Skip to content
Drug Policy Watch™
LatestTracking drug policy in all 50 states and Congress, updated every morning.See all ›
Drug Policy Watch · State Brief 2026

New Jersey

Snapshot (structured)

Adult-use cannabis
Legal (legalized by 2020 ballot question, retail sales began April 2022)
Medical cannabis
Legal (since 2010, Compassionate Use Medical Marijuana Act)
Home grow
Not allowed (prohibited for both adult-use and medical patients; multiple 2026 bills pending)
Intoxicating hemp / hemp THC
Heavily restricted (S4509 signed January 12, 2026, moved intoxicating hemp into the licensed cannabis system; total-THC standard)
Psychedelics
Limited therapeutic pilot only (psilocybin research pilot signed January 2026); no decriminalization
Broad decriminalization
No general drug decriminalization; cannabis decriminalized; broader possession remains criminal
Harm reduction
Strong (statewide syringe services authorized in all counties, naloxone access, fentanyl and xylazine test strips legal)
Governor (party)
Mikie Sherrill (Democrat), inaugurated January 20, 2026
Legislature control
Democratic (both chambers)
Citizen ballot initiatives allowed
No (New Jersey has no citizen-initiated statute or constitutional amendment process; amendments are legislatively referred)
Enclosure pressure score
4/5

Cannabis

New Jersey legalized adult-use cannabis through a 2020 constitutional ballot question approved by voters, with the implementing CREAMM Act (Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act) following. Legal adult-use retail sales began in April 2022. Medical cannabis has been legal since 2010 under the Compassionate Use Medical Marijuana Act (later expanded by the 2019 Jake Honig Act). The market is regulated by the Cannabis Regulatory Commission (CRC), which oversees both medical and adult-use programs.

Home grow remains illegal for both adult-use consumers and registered medical patients, making New Jersey one of the few legal-cannabis states with no home cultivation right (https://www.mpp.org/states/new-jersey/, https://thelibrarynj.com/blog/nj-cannabis-home-grow-2025/).

Market structure: As of December 2025 the state had issued roughly 2,435 cannabis licenses with about 397 operational, and licensed businesses operating in roughly 211 municipalities (https://cannabiswiseguys.com/new-jersey/, https://www.nj.gov/cannabis/highpoints/20260206.shtml). In 2025 the industry generated more than $1.16 billion in sales (https://cannabiswiseguys.com/new-jersey/). Taxes: 6.625% state sales tax applies, plus a local cannabis transfer tax capped at 2% for cultivators/manufacturers/retailers and 1% for wholesalers, plus the CRC Social Equity Excise Fee (SEEF), set at roughly $2.50 per ounce for 2026 (https://cannabispromotions.com/taxes/states/new-jersey, https://tcadvisorscpa.com/cannabis-business-accounting-tax-compliance-nj/). Municipal opt-in is required, and many towns that opted in do not permit all license classes, which constrains vertical integration and pushes consumers between municipalities (https://cannabiswiseguys.com/new-jersey-municipalities/).

Key 2026 actions: In November 2025 both chambers passed S4847/A6267, a CRC modernization bill that, among other things, raised the retail license cap from one wholly owned Class 5 Retail Dispensary to three (authorizing up to two satellite retail locations), added illicit-cannabis enforcement, tightened hemp regulation, updated advertising rules, and expanded labor oversight (https://foleyhoag.com/news-and-insights/blogs/cannabis-and-the-law/2026/january/new-jersey-legislative-changes-implement-growth-and-opportunity-for-cannabis-marketplace/, https://newjerseystatecannabis.org/news-12nov2025). In January 2026 Governor Murphy signed cannabis worker labor-rights legislation (https://www.roi-nj.com/2026/01/13/industry/gov-murphy-signs-cannabis-worker-protections-into-law/). The final signature status of S4847 itself by Murphy before he left office is unconfirmed in available sourcing; the live tracker is at https://www.billtrack50.com/billdetail/1910440.

Hemp

On January 12, 2026, Governor Phil Murphy signed S4509, which rewrote New Jersey's definition of "hemp" to a total-THC standard (no more than 0.3% total THC, counting all THC isomers and analogs including THCA post-decarboxylation) and pulled intoxicating hemp products into the licensed cannabis regulatory system (https://www.cannabisregulations.ai/cannabis-and-hemp-regulations-compliance-ai-blog/new-jersey-hemp-thca-ban-2026, https://www.law360.com/articles/2429329/nj-gov-signs-bill-regulating-intoxicating-hemp-products). Reporting also references prior bill S3235 in this regulatory chain (https://www.cannabisregulations.ai/cannabis-and-hemp-regulations-compliance-ai-blog/new-jersey-intoxicating-hemp-ban-2025-emergency-rules-enforcement).

Phased effective dates as reported: immediate bans on synthesized cannabinoids (delta-8 from CBD, HHC, etc.) and on online sales of hemp-derived products took effect around January 13, 2026; the broader ban on intoxicating hemp products (THCA, delta-8, etc.) outside the licensed system took effect April 13, 2026; and the prohibition on intoxicating hemp beverages becomes effective November 13, 2026, after which hemp beverages exceeding 0.4 mg total THC per container are treated as cannabis (https://www.cannabisregulations.ai/cannabis-and-hemp-regulations-compliance-ai-blog/new-jersey-hemp-thca-ban-2026). Violations carry penalties reported at up to $10,000 per violation plus possible license revocation (same source). Note: these specific dates come from a single industry compliance source and should be confirmed against the enacted statute text before relying on them.

Federal exposure: New Jersey's move closely parallels the federal change. Congress passed a narrowed federal hemp definition on November 12, 2025, signed by President Trump, shifting from a delta-9-only 0.3% dry-weight standard to a total-THC standard and capping finished consumable hemp products at 0.4 mg total THC per container, with a one-year delayed implementation date of November 12, 2026 (https://www.congress.gov/crs-product/IN12620, https://vicentellp.com/insights/2026-federal-hemp-ban-what-it-means-for-the-future-of-consumable-hemp-products/, https://thehazeconnect.com/blogs/learn/november-12-2026-federal-hemp-deadline-every-state). Because New Jersey has already routed intoxicating hemp into its licensed cannabis system, the state is comparatively well positioned for the federal deadline, though hemp beverage operators face the November 13, 2026 state cutoff in parallel.

Psychedelics

New Jersey has not decriminalized psychedelics and has not created broad therapeutic access. In January 2026, the Legislature passed and Governor Murphy signed (on or about January 20, 2026, shortly before leaving office) a bill establishing a narrow, state-run, hospital-based psilocybin research pilot. Reporting identifies the vehicle as S2283, the Psilocybin Behavioral Health Access and Services Act, which establishes a pilot program and appropriates $6 million (often described as funding three hospital pilots at roughly $2 million each across three geographic regions) and creates a Psychedelic Therapy and Research Advisory Board (https://www.marijuanamoment.net/new-jersey-governor-signs-bill-creating-psilocybin-therapy-pilot-program-and-allocating-6-million-to-psychedelic-treatment-effort/, https://psychedelicstoday.com/2026/01/21/did-new-jersey-really-just-legalize-psilocybin/). Sponsors are reported as Senate President Nicholas Scutari (D) and Sen. Joseph Vitale (D), with Assemblymembers Clinton Calabrese (D) and Anthony Verrelli (D) (https://www.marijuanamoment.net/new-jersey-lawmakers-approve-bill-to-legalize-psilocybin-therapy/). Note: the bill number/title pairing (S2283 vs the earlier broader framework) is somewhat tangled in the reporting; treat the exact enacted vehicle as needing confirmation against njleg.state.nj.us.

The pilot does not legalize, decriminalize, or broadly authorize access, and provides no record relief for prior psilocybin offenses (https://psychedelicstoday.com/2026/01/21/did-new-jersey-really-just-legalize-psilocybin/). Separately, Scutari and Vitale have reportedly pre-filed a broader follow-on bill (referenced as S3148, the Psilocybin Behavioral Health Access and Services Act) aimed at a more expansive access framework; status unconfirmed (https://www.psychedelicamericas.org/p/nj-psilocybin-legislation-exposes-conflicts-between-advocates-for-different-therapeutic-models).

Broader drug policy

There is no general drug decriminalization in New Jersey; possession of controlled substances other than cannabis remains criminal. Cannabis itself is decriminalized and legal for adults.

Harm reduction is comparatively strong. In March 2025 the state Department of Health authorized harm reduction centers in all 21 counties (https://www.nj.gov/health/news/2025/approved/20250326a.shtml). Syringe services programs provide syringe access and disposal, referrals, counseling, fentanyl test strips, and HIV/Hepatitis C testing (https://njharmreduction.org/syringe-access/). In January 2024 Governor Murphy signed legislation expanding the harm reduction supplies that centers may distribute, including materials to test for xylazine (https://web.archive.org/web/20250908124519/https://www.nj.gov/governor/news/news/562024/20240108e.shtml). Naloxone access is broad. The state reported declining overdose deaths across racial and ethnic groups alongside the county expansion (https://www.nj.gov/health/news/2025/approved/20250326a.shtml).

Sentencing and expungement: New Jersey's CREAMM Act mandated automatic expungement of many past cannabis convictions, and the state Supreme Court has ordered expungement of tens of thousands of cannabis cases. Eligible records include possession of up to 6 ounces and distribution of up to 1 ounce, among related minor offenses; residents can track status via the State Police expungement portal (expgportal.nj.gov) (https://thelibrarynj.com/blog/nj-cannabis-laws-2026-complete-guide/, https://www.njcourts.gov/public/news-media/top-news/marijuana-record-expungement).

Political landscape

Governor: Mikie Sherrill (Democrat), New Jersey's 57th governor, inaugurated January 20, 2026, succeeding two-term Democrat Phil Murphy (https://edition.cnn.com/2026/01/20/politics/mikie-sherrill-new-jersey-governor, https://whyy.org/articles/mikie-sherrill-new-jersey-governor-sworn/).

Legislature: Democrats control both chambers in the 222nd Legislature, which convened January 13, 2026. After the November 2025 election, Democrats hold a 57-23 majority in the 80-seat General Assembly; the 40-seat Senate (last elected in 2023, next up in 2027) stands at 25 Democrats to 15 Republicans (https://en.wikipedia.org/wiki/2025_New_Jersey_General_Assembly_election, https://ballotpedia.org/2026_New_Jersey_legislative_session, https://en.wikipedia.org/wiki/222nd_New_Jersey_Legislature).

Reform champions (named): Senate President Nicholas Scutari (D) was the lead architect of New Jersey cannabis legalization and is the lead psilocybin sponsor; Sen. Joseph Vitale (D, chair of Senate Health) co-sponsors the psilocybin measures; Assemblymembers Clinton Calabrese (D) and Anthony Verrelli (D) are psilocybin co-sponsors (https://www.marijuanamoment.net/new-jersey-lawmakers-approve-bill-to-legalize-psilocybin-therapy/). Sen. Holly Schepisi (R) has publicly supported the psilocybin bill (https://video.wedu.org/video/sen-holly-schepisi-on-why-she-supports-psilocybin-bill-1fisgi). Key committees include Senate Judiciary (handling home-grow bill S2564) and Senate Health, Human Services and Senior Citizens (handling S1758). Named opponents and Governor Sherrill's specific cannabis/psychedelic positions are unconfirmed in available 2026 sourcing.

Ballot initiatives

New Jersey does not allow citizen-initiated ballot measures. There is no statutory initiative or citizen-initiated constitutional amendment process; constitutional amendments reach the ballot only when referred by the Legislature (the 2020 cannabis legalization question was a legislatively referred constitutional amendment). Consequently there are no pending citizen-initiated 2026 cannabis, psychedelic, or drug-policy ballot measures. Any future measure on these topics would require legislative referral.

Equity and expungement

Social equity is built into the CREAMM Act licensing framework. Social Equity Applicants qualify by having a prior cannabis-related conviction (in any US jurisdiction) or by residing in a designated "Impact Zone" / economically disproportionately impacted area for 5 of the last 10 years, subject to income limits; such applicants receive priority licensing (https://thelibrarynj.com/blog/nj-cannabis-laws-2026-complete-guide/). The state expungement portal helps applicants document Impact Zone residency or qualifying convictions (same source).

On records, the CREAMM Act provides automatic expungement of many prior cannabis offenses (possession up to 6 ounces, distribution up to 1 ounce, and related minor offenses), and the Supreme Court has ordered expungement of tens of thousands of cases (https://www.njcourts.gov/public/news-media/top-news/marijuana-record-expungement, https://www.nj.gov/cannabis/documents/Resources/2023-1-6%20Automatic%20Expungement%20of%20Marijuana%20Record.pdf). Who is excluded: the psilocybin pilot provides no record relief for prior psilocybin offenses, and non-cannabis drug offenses are not covered by the cannabis automatic-expungement regime.

Market and barriers

Taxes: state sales tax 6.625%; local cannabis transfer tax capped at 2% (cultivators/manufacturers/retailers) and 1% (wholesalers); SEEF roughly $2.50/oz for 2026 (https://cannabispromotions.com/taxes/states/new-jersey, https://tcadvisorscpa.com/cannabis-business-accounting-tax-compliance-nj/). Federal 280E continues to burden operators (same TC Advisors source).

Licensees: roughly 2,435 licenses issued and about 397 operational as of late 2025, across roughly 211 municipalities (https://cannabiswiseguys.com/new-jersey/). License caps: retail ownership cap raised from 1 to 3 (with up to 2 satellite locations) under S4847 (https://foleyhoag.com/news-and-insights/blogs/cannabis-and-the-law/2026/january/new-jersey-legislative-changes-implement-growth-and-opportunity-for-cannabis-marketplace/). Specific 2026 application fee schedules, capital requirements, and residency requirements were not confirmed in available sourcing and should be checked against current CRC rules (https://www.nj.gov/cannabis/). Municipal opt-in and uneven license-class permissions remain a structural barrier, especially for smaller and vertically integrating operators (https://cannabiswiseguys.com/new-jersey-municipalities/).

Enclosure read

New Jersey sits at the more fenced end of the spectrum. Three dynamics dominate. First, the absence of any home grow right means consumers and patients are fully dependent on the licensed commercial market, with no personal-cultivation escape valve, an unusual posture for a legal state. Second, the January 2026 hemp overhaul (S4509) and the parallel federal total-THC standard effective November 12, 2026 collapse the independent intoxicating-hemp channel into the licensed cannabis system, fencing out smoke shops, hemp retailers, and small CBD/delta-8 businesses while consolidating intoxicating-cannabinoid commerce inside CRC-licensed operators. Third, municipal opt-in plus uneven license-class permissions favor better-capitalized and multi-location operators, an effect amplified by the new 1-to-3 retail cap that lets existing license holders expand their footprint. Counterweights keep this from a 5: robust social-equity licensing, strong automatic expungement, and broad harm reduction. On balance the structural fencing of supply (no home grow, hemp folded into the licensed system, capital-heavy municipal gatekeeping) outweighs the equity provisions, yielding an enclosure pressure score of 4/5.

What to watch next

Regulators

Federal exposure (2026)

New Jersey's exposure to federal levers in 2026 runs across every major front.

Rescheduling and 280E. Cannabis remains Schedule I by default. On April 22, 2026 the DOJ and DEA signed an order moving only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III, ending Section 280E for that medical category effective April 28, 2026; adult-use (recreational) cannabis stays Schedule I and stays under 280E (https://www.justice.gov/opa/pr/justice-department-places-fda-approved-marijuana-products-and-products-containing-marijuana, https://foleyhoag.com/news-and-insights/blogs/cannabis-and-the-law/2026/april/doj-immediately-reschedules-state-licensed-medical-cannabis-to-schedule-iii-and-restarts-the-clock/, https://www.mpp.org/policy/federal/doj-reschedules-state-legal-medical-cannabis-to-schedule-iii-questions-and-answers/). New Jersey runs both programs through one regulator, the Cannabis Regulatory Commission, and most operators hold adult-use as well as medical authorizations, so the medical-only relief is partial and bookkeeping-bound: an operator can shed 280E only on the medical share of its activity that is "subject to a qualifying state-issued license," not on its recreational sales, which forces line-item separation of medical from adult-use revenue and cost of goods. Vertically structured multi-license operators with real medical volume capture the most relief; adult-use-only retailers capture none. The broader DEA hearing on moving all cannabis to Schedule III opened June 29, 2026 and may slip to 2027; Schedule III, if it ever reaches recreational cannabis, would still not legalize it, would not authorize interstate commerce, and would not cover state recreational businesses (https://www.gibsondunn.com/dea-downschedules-state-medical-marijuana-to-schedule-iii-expedited-hearing-set-to-consider-broader-rescheduling/).

The November 12, 2026 hemp cliff. FY2026 agriculture appropriations (Sec. 781, sponsor reported as Rep. Andy Harris, R-MD; confirm sponsor against enacted text) narrowed federal hemp to a total-THC standard of roughly 0.4 mg THC per container, recriminalizing an estimated 90 to 95 percent of intoxicating hemp products effective November 12, 2026; the H.R.7010 delay was not enacted, and the 2026 Farm Bill vehicle (reported as H.R.7567; confirm) keeps the ban (https://www.congress.gov/crs-product/IN12620, https://thehazeconnect.com/blogs/learn/november-12-2026-federal-hemp-deadline-every-state). New Jersey had already folded intoxicating hemp into its licensed cannabis system via S4509, signed January 12, 2026, on a matching total-THC standard, so the federal ban aligns with state law rather than colliding with it (https://www.law360.com/articles/2429329/nj-gov-signs-bill-regulating-intoxicating-hemp-products). Practical effect: the federal cliff does not open a new gap in New Jersey, because the independent intoxicating-hemp channel is already closing into the CRC system on a parallel state timeline (reported state effective dates running through November 13, 2026; confirm against enacted text) (https://www.cannabisregulations.ai/cannabis-and-hemp-regulations-compliance-ai-blog/new-jersey-hemp-thca-ban-2026). New Jersey hemp retailers, smoke shops, and small CBD and delta-8 sellers lose the product line under both regimes at once; the surviving intoxicating-cannabinoid commerce sits inside CRC-licensed operators. Compliant non-intoxicating hemp (fiber, grain, low-THC CBD) is unaffected.

Banking. SAFER Banking has stalled in Congress, so New Jersey cannabis operators, medical and adult-use alike, remain largely cut off from mainstream banking, card payment rails, and ordinary lending, which raises cash-handling risk and capital costs and structurally favors well-capitalized incumbents over thin-margin new entrants and social-equity licensees. The medical Schedule III move does not fix this; banking access turns on the SAFER Banking statute, not on scheduling.

Psychedelics. Psilocybin, MDMA, and ibogaine all remain Schedule I federally. An April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority vouchers fast-track FDA review, but there is no federal approval yet (federal pathway is review-track only). New Jersey's January 2026 hospital-based psilocybin research pilot (reported vehicle S2283; see Psychedelics section) operates as state-authorized research under continuing federal Schedule I status, so it depends on DEA research registration and federal research handling rather than any federal legalization, and it confers no commercial or general-access right (https://www.marijuanamoment.net/new-jersey-governor-signs-bill-creating-psilocybin-therapy-pilot-program-and-allocating-6-million-to-psychedelic-treatment-effort/).

Harm reduction. New Jersey's harm reduction posture is strong, with Department of Health authorized syringe services in all 21 counties, broad naloxone access, and legal fentanyl and xylazine test strips (https://www.nj.gov/health/news/2025/approved/20250326a.shtml, https://njharmreduction.org/syringe-access/). This is directly exposed to the April 24, 2026 SAMHSA guidance barring federal funds for fentanyl test strips, clean syringes, and sterile water; naloxone remains federally supported. To the extent New Jersey syringe services and test-strip distribution lean on federal dollars, that funding stream is now closed, shifting the burden onto state and local appropriations and private funders; the legal authorization stands, but the federal money behind core supplies does not.

Fentanyl. The HALT Fentanyl Act (signed July 17, 2025) permanently placed fentanyl-related substances in Schedule I, which reinforces the criminal exposure of non-cannabis drug activity that New Jersey has not decriminalized and sits underneath the state's harm reduction work rather than displacing it.

Patient access and rights

This section covers what New Jersey law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): New Jersey has no hospital-access law. No statute requires a hospital, nursing home, or hospice to let a qualifying patient use medical cannabis on site, so whether a facility allows it is left to that facility's own policy, and many refuse. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), and Pennsylvania has a bill pending; New Jersey is not among them. The absence is the finding: a New Jersey patient has no enforceable right to use their medicine in a hospital today.

Broader protections: here New Jersey is comparatively strong across all six areas. The employment protection sits in its own statute, N.J.S.A. 24:6I-6.1, which bars an employer from taking adverse action based solely on a person's status as a registered patient or a positive cannabis test, subject to a lawful drug-testing process. The remaining protections sit in N.J.S.A. 24:6I-6: a landlord or a school may not refuse a person solely for being a registered patient (subsections (h) and (i)), custody and parenting time are protected (subsection (m)), and for the purposes of medical care, including organ transplants, authorized use is treated as the equivalent of any other prescribed medication (subsection (g)). A New Jersey patient cannot be denied a transplant listing solely for lawful medical cannabis use.

Out-of-state patients: New Jersey issues a temporary visiting-patient registration, valid for six months, that lets an out-of-state patient use the medical program while in New Jersey.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine and does not create any hospital-use right; only state law can force hospital access, and New Jersey has not enacted a Ryan's Law. The broader protections above are a creature of New Jersey law, not federal law.

Sources: New Jersey employment protection, N.J.S.A. 24:6I-6.1; other patient protections, N.J.S.A. 24:6I-6.

Related reading from Drug Policy Watch: the Federal Drug Policy Brief, the Schedule III rescheduling explainer, and the 50-State Matrix.

Analysis: the enclosure read in depth

New Jersey is one of the more enclosed legal-cannabis states, and the 2026 federal moves tighten rather than loosen that read.

Who is fenced out. Consumers and patients have no escape valve at all: New Jersey allows no home grow for adult-use or for registered medical patients, so the only lawful supply is the CRC-licensed commercial market. That is the foundational enclosure, more complete than in legal states that at least permit personal cultivation. On the supply side, the people fenced out are the small and independent actors. The hemp overhaul (S4509) plus the matching federal total-THC standard erase the independent intoxicating-hemp lane, pushing those products into CRC licensure or out of business and ending the cheap, low-barrier route that smoke shops and small CBD and delta-8 sellers had used to reach consumers. Stalled SAFER Banking keeps banking, payments, and lending scarce, which disproportionately burdens undercapitalized and social-equity entrants. Municipal opt-in plus uneven license-class permissions add a capital-and-zoning gate that rewards multi-location, better-financed operators.

Who consolidates. The CRC-run market is the consolidation point. The S4847 increase in the retail ownership cap from one to three (with up to two satellite locations) lets existing license holders expand their footprint. The medical-only Schedule III relief flows to operators with genuine medical volume inside a vertically structured book, not to single-store adult-use retailers, so it nudges the market toward larger, dual-program, vertically integrated incumbents. The hemp fold-in routes previously independent intoxicating-cannabinoid demand to those same CRC licensees. Each 2026 lever, scheduling, hemp, banking, points value toward the larger incumbent inside the licensed system.

State-plus-federal interaction. The distinctive New Jersey feature is alignment rather than friction. The federal hemp cliff lands on a state that already closed the same channel on a parallel timeline, so there is no regulatory gap to exploit and no whipsaw, just a cleaner, earlier enclosure. The federal medical Schedule III move interacts awkwardly with New Jersey's single-regulator, dual-program structure, delivering real but partitioned 280E relief that must be carved out medical-from-recreational. Banking and the SAMHSA harm reduction cuts are pure federal headwinds the state cannot fix alone; New Jersey can keep its authorizations on the books but cannot restore the federal money or the banking access.

What to watch. Whether the home-grow bills (reported S2564, S1758, A1674; sponsors unconfirmed) advance out of committee would be the single largest commons counter-move available, since home cultivation is the one lever that breaks total dependence on the licensed market. Watch the June 29, 2026 DEA hearing for any path toward recreational Schedule III (still not legalization). Watch whether New Jersey backfills SAMHSA-cut harm reduction supplies with state or local funds. Watch CRC implementation of the hemp fold-in and the retail-cap expansion for whether consolidation accelerates.

Where commons counter-moves are present or absent. Present: strong automatic cannabis expungement, social-equity priority licensing, and a robust harm reduction framework in all 21 counties are real counterweights that distribute benefit and reduce criminal exposure. Absent: there is no home grow, no citizen ballot-initiative process to force a more open market from outside the Legislature, no record relief for psilocybin or non-cannabis offenses, and no state fix for the federal banking and harm reduction funding gaps.

Justifying the enclosure score. The structural fencing of supply is severe: no home grow at all, intoxicating hemp folded into the licensed system in step with the federal cliff, capital-and-zoning municipal gatekeeping, scarce banking, and 2026 federal moves that all flow value to large incumbents inside the CRC market. The equity provisions (expungement, social-equity licensing) and strong harm reduction are genuine but do not open the supply side; they soften the edges of an enclosed market rather than opening it. That balance, heavy supply enclosure partly offset by real equity and harm reduction counterweights, holds the score at 4 of 5 rather than a maximal 5.

Active legislation (2026)

This list is not exhaustive. For the long tail, see LegiScan (https://legiscan.com/NJ), the New Jersey Legislature site (https://www.njleg.state.nj.us).

Beyond the live tracker

These measures are not in the live bill list below: some are not bills (executive orders, rules, referendums, or budgets), and some are proposals or prior-session measures the live tracker does not currently carry.

  • Cannabis worker labor-rights act Extends labor rights/protections to cannabis workers (Signed January 13, 2026)
Bill Title/Topic Chamber Status Sponsor(s)
S4847 / A6267 CRC modernization; retail license cap 1 to 3 plus satellites; hemp regulation; illicit-market enforcement; labor Both (passed Nov 12, 2025) Passed both chambers; signature status by Murphy unconfirmed Unconfirmed (see tracker https://www.billtrack50.com/billdetail/1910440)
S4509 Redefines hemp to total-THC standard; routes intoxicating hemp into licensed cannabis system Both Signed January 12, 2026 Unconfirmed
S2283 Psilocybin Behavioral Health Access and Services Act; hospital pilot; $6M; advisory board Both Signed on/about January 20, 2026 Scutari (D), Vitale (D); Asm. Calabrese (D), Verrelli (D)
S3148 Broader follow-on psilocybin access framework Senate Pre-filed; status unconfirmed Scutari (D), Vitale (D) (reported)
S2564 Adult-use home grow (up to 6 plants/adult, 12/household) Senate In Senate Judiciary Committee (introduced Jan 2026) Unconfirmed
S1758 Medical patient home cultivation (companion to A1674) Senate In Senate Health, Human Services and Senior Citizens Committee Unconfirmed
A1674 Medical patient home cultivation (4 mature / 4 immature plants) Assembly Under consideration (2026 session) Unconfirmed
Cannabis worker labor-rights act Extends labor rights/protections to cannabis workers Both Signed January 13, 2026 Unconfirmed

Sources: https://foleyhoag.com/news-and-insights/blogs/cannabis-and-the-law/2026/january/new-jersey-legislative-changes-implement-growth-and-opportunity-for-cannabis-marketplace/, https://necann.com/cannabis-news/nj-bill-proposes-home-cannabis-cultivation/, https://www.marijuanamoment.net/home-cultivation-of-marijuana-would-be-legalized-in-new-jersey-under-lawmakers-proposals/, https://www.roi-nj.com/2026/01/13/industry/gov-murphy-signs-cannabis-worker-protections-into-law/

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →

Sources